Who is sponsoring NCT05890872?

NCT05890872 is sponsored by Galvanize Therapeutics, Inc..

What drugs are being tested in NCT05890872?

Interventions in NCT05890872: Aliya Pulsed Electric Fields (PEF).

What condition does NCT05890872 study?

NCT05890872 studies Lung Neoplasm Malignant.

Is NCT05890872 still recruiting?

NCT05890872 is currently completed. Last updated 20 August 2025.

Last reviewed 2025-08-20 · How we verify

NCT05890872: AFFINITY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer

Completed NA Last updated 20 August 2025

What this trial tests

NA trial testing Aliya Pulsed Electric Fields (PEF) in Lung Neoplasm Malignant in 30 participants. Completed in 13 August 2025.

Timeline

6 September 2023

Primary endpoint
13 August 2025

13 August 2025

Quick facts

Lead sponsor	Galvanize Therapeutics, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	6 September 2023
Primary completion	13 August 2025
Estimated completion	13 August 2025
Sites	5 locations across United States

Drugs / interventions tested

Aliya Pulsed Electric Fields (PEF)

Conditions studied

Lung Neoplasm Malignant — all drugs for Lung Neoplasm Malignant →

Sponsor

Galvanize Therapeutics, Inc. — full company profile →

Who can join

22 and older, any sex, with Lung Neoplasm Malignant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate safety of delivering Aliya PEF in patients with metastatic cancer within the lungs or stage IV non-small cell lung cancer (NSCLC) who are treatment-naïve and indicated for first-line standard of care (SOC) cancer therapy.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Robotic-assisted bronchoscopy: a narrative review of systems.
Fernandez-Bussy S, Chandra NC, Koratala A, Yu Lee-Mateus A, et al · · 2024 · cited 19× · PMID 39268090 · DOI 10.21037/jtd-24-456
Safety and Feasibility of Pulsed Electric Field Ablation for Early-Stage Non-Small Cell Lung Cancer Prior to Surgical Resection.
Jimenez M, Flandes J, van der Heijden EHFM, Ng CSH, et al · · 2025 · cited 9× · PMID 40152831 · DOI 10.1002/jso.28110
Pulsed Electric Field (PEF) treatment of progressive non-small cell lung cancer concurrently treated with immune checkpoint blockade: A case report.
Jimenez M, Fernandez JM, Krimsky WS. · · 2024 · cited 7× · PMID 38601720 · DOI 10.1016/j.rmcr.2024.102018
Robotic-assisted bronchoscopy-advancing lung cancer management.
Chang ATC, Chan JWY, Siu ICH, Liu W, et al · · 2025 · cited 3× · PMID 40529888 · DOI 10.3389/fsurg.2025.1566902
Robotic-assisted and electromagnetic navigation bronchoscopy for multi-focal lung cancers: a narrative review.
Liu W, Chang ATC, Chan JWY, Lau RWH, et al · · 2025 · PMID 41367580 · DOI 10.21037/tlcr-2025-943
Six-Month Local Control Rates and Immune Responses After Pulsed Electric Field Ablation in Metastatic Cancer.
Moreno-Gonzalez A, Nafie EHO, Pastori C, Mammarappallil J, et al · · 2025 · PMID 41228287 · DOI 10.3390/cancers17213495

Verify or expand the search:

Other recruiting trials for Lung Neoplasm Malignant

Currently open trials in the same condition.

NCT07286149 — A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) · Phase 1, PHASE2 · recruiting
NCT07071103 — Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors · Phase 2 · recruiting
NCT06788912 — Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAK · Phase 2 · recruiting
NCT06440616 — Benefit of Spectral Information in Patients Suspected for Lung Cancer · NA · recruiting
NCT06079970 — Confocal Laser Endomicroscopy VERification · NA · recruiting

Other Galvanize Therapeutics, Inc. trials

Trials by the same sponsor.

NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT05851430 — Galvanize Prospective/Retrospective Pulsed Electric Field Device Registry · recruiting
NCT05583188 — Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC · Phase 4 · terminated
NCT04773275 — A Clinical Evaluation of the Aliya™ System in Late Stage Cancer · NA · terminated
NCT04732520 — Feasibility Study of the Aliya System in the Treatment of Early Stage Non-small Cell Lung Cancer · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05890872 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 21 May 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Galvanize Therapeutics, Inc.
Last refreshed: 20 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05890872.